HBW Insight Mentions First Insight | Private Label 'Smart Imitation' Of National Brands' Packaging Not So Wise In US OTC Drug Sector
First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.